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Abstract
Introduction: Duplicate measurements can be used to describe the performance and analytical robustness of assays and to identify outliers. We 
performed about 235,000 duplicate measurements of nine routinely measured quantities and evaluated the observed differences between the re-
plicates to develop new markers for analytical performance and robustness.
Materials and methods: Catalytic activity concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and concentra-
tions of calcium, cholesterol, creatinine, C-reactive protein (CRP), lactate, triglycerides and thyroid-stimulating hormone (TSH) in 237,261 patient 
plasma samples were measured in replicates using routine methods. The performance of duplicate measurements was evaluated in scatterplots 
with a variable and symmetrical zone of acceptance (A-zone) around the equal line. Two quality markers were established: 1) AZ95: the width of an 
A-zone at which 95 % of all duplicate measurements were within this zone; and 2) OPM (outliers per mille): the relative number of outliers if an A-
zone width of 5 % was applied.
Results: The AZ95 ranges from 3.2% for calcium to 11.5% for CRP and the OPM from 5 (calcium) to 250 (creatinine). Calcium, TSH and cholesterol 
have an AZ95 of less than 5% and an OPM of less than 50.
Conclusions: Duplicate measurements of a large number of patient samples identify even low frequencies of extreme differences and thereof de-
fined outliers. We suggest two additional quality markers, AZ95 and OPM, to complement description of assay performance and robustness. This 
approach can aid the selection process of measurement procedures in view of clinical needs.
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Internal quality control schemes (IQC), e.g. West-
gard or the Guidelines for Quality Assurance of 
Medical Laboratory Examinations of the German 
Medical Association (RiliBÄK), have a long tradition 
in clinical chemistry to monitor the reliability of 
measurements and have proved to provide a rea-
sonable quality control (1-3). The Clinical & Labora-
tory Standards Institute (CLSI) has advised proce-
dures to verify the trueness and precision of rou-
tine methods (4). The schemes rule that IQC sam-
ples are measured at certain intervals, defined ei-
ther by time or by number of measured patient 
samples. Therefore, IQC may fail to detect occa-
sional dropouts, i.e. outliers among routine sam-
ples, which may cause erroneous clinical decisions 
in patient care (4-15). To identify outliers, duplicate 
measurements may be used (16-20), but are often 
refrained from, due to economic pressure (21,22). 
Outliers are differently defined in the literature 
and their frequencies are reported by various ap-
proaches (1,2,4,5,16-19,23-26). Additionally, what is 
perceived as an outlier may vary depending on 
the analyte or diagnosis (2,4,16-19,24,27). By de-
scribing magnitude and number of differences be-
tween duplicate measurements, laboratories and 
clinicians can define the difference they consider 
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an outlier and consequently estimate the frequen-
cy they will experience (27). If based on a sufficient 
number, duplicate measurements have the poten-
tial to reveal even low frequencies of outliers (4,20).
In the present study, we report a large number of 
duplicate measurements in patient plasma sam-
ples under routine conditions in nine commonly 
used assays. It is an extension of a study published 
in 2013, where these investigations were per-
formed with one glucose assay (27). To broaden 
the findings from the glucose study, further fre-
quently used assays were investigated and com-
pared. Since only measurements with valid IQC 
shall be included, the performance observed in 
the study reflects the currently accepted frequen-
cy and magnitude of extreme differences. Our aim 
was to detect even low frequencies of outliers and 
their magnitude in routine assays and to derive 
new quality markers for assay performance that 
give more detailed information than the regular 
IQC. Our approach aims at complementing de-
scription of performance and analytical robust-
ness of assays.
Materials and methods
The plasma samples were from an unselected 
population of hospitalized patients and outpa-
tients at the University Medicine of Greifswald 
(Germany). During twelve consecutive months, 
starting in December 2011 the catalytic activity 
concentrations and concentrations of aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), and concentrations of calcium, cholesterol, 
creatinine, C-reactive protein (CRP), lactate, triglyc-
erides and thyroid-stimulating hormone (TSH) 
were routinely measured in duplicates on a 24/7 
basis. Assays were run on three Dimension Vista 
1500 instruments using procedures and reagents 
according to the manufacturer ś instruction (Sie-
mens Healthcare Diagnostics, Eschborn, Germa-
ny). The instruments were connected to Stream-
LAB (Siemens Healthcare Diagnostics, Eschborn, 
Germany) which allocated the samples to one of 
the three instruments. Once allocated to a specific 
instrument, the duplicate measurements were au-
tomatically ordered and performed on this same 
instrument by two sample aspirations but only the 
first obtained result was released for patient care. 
Only measurements within concentration intervals 
according to RiliBÄK (published in RiliBÄK ś Table 
B1, column 4: “RiliBÄK applicable concentration in-
tervals of columns 3 and 5”), specific for each ana-
lyte, and only measurements with valid IQC ac-
cording to the RiliBÄK were included in the study 
(3). TRU-Liquid Monitrol (lot 1AQ104) was used as 
IQC material for ALT, AST, calcium, cholesterol, cre-
atinine, lactate, Triglycerides; Liquimmune (lot 
9LQ105, both Thermo Fisher Scientific, Schwerte, 
Germany) for TSH and Protein2 (lot 1LQH01, Sie-
mens Healthcare Diagnostics, Eschborn Germany) 
for CRP. Imprecision was calculated from IQC for 
each analyte, IQC level (high and low) and RiliBÄK 
monthly control cycle. Samples were anonymized 
prior to data collection.
Data analysis was performed using Microsoft Ex-
cel® (2010). Ethical approval of the local ethics com-
mittee was obtained.
For each assay, differences or agreements of dupli-
cate measurements were summarized in scatter 
plots including regression and correlation analy-
ses. To categorize the observed differences be-
tween the duplicates with respect to their magni-
tude, a zone surrounding the equal line of the 
scatter plots was used (Figure 1). This area is often 
referred to as the A-zone (28). The A-zone (dotted 
lines Figure 1) is located around the equal line 
(hatched line Figure 1) of duplicate measurements, 
with the first measurement on the X-axis and the 
second measurement on the Y-axis. The A-zone 
width can be modified symmetrically around the 
equal line as indicated by the arrows. The triangles 
represent a duplicate measurement within the 
chosen A-zone whereas the square represents a 
duplicate measurement outside the A-zone. 
In this study its width was systematically modified 
and increased to the width of 14% (Figure 2). Dif-
ferences outside the chosen A-zone were regard-
ed as outliers. Thus, the definition of an outlier de-
pends on the width of the A-zone. A narrow A-
zone consequently corresponds to strict limits and 
would cause small differences to be regarded as 
outliers whereas a wide A-zone allows large differ-
ences. 
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At each A-zone width, differences that fell outside 
this area were counted. The relative numbers of 
observations outside the various A-zones were 
plotted against the width of the A-zone (Figure 2). 
Two quality markers can be derived from this ap-
proach and used to describe performance and an-
alytical robustness of assays: 
1. AZ95 (A-zone 95%): The width of the A-zone at 
which 95% of all duplicate measurements are 
within this zone (Figure 2, the A-zone width can 
be read from the x-axis where the respective 
analyte curve crosses the red horizontal line. 
This horizontal line crosses the y-axis at 50 OPM 
since this represents 50 out of 1000 i.e. 95%),
2. OPM (outlier per mille): The relative number of 
outliers in per mille if an A-zone width of 5% is 
used to identify outliers (Figure 2, the relative 
number of outliers can be read from the y-axis 
where the respective curve crosses the red ver-
tical line).
The common target is 95% of the observations 
within an A-zone of 5%, which is already described 
in the CLSI EP 27 guidelines (28) and means in our 
study a maximum AZ95 of 5% and at the same 
time a maximum OPM of 50. For the comparison 
between different analytes it is important to con-
sider, that individual clinical requirements induce 
different requirements for the AZ95 and the OPM 
of each analyte.
Results
The number of plasma samples run in duplicates 
ranged from 1596 for lactate to 73,242 for creati-
nine (Table 1); in total, 237,261 duplicates were 
measured. The imprecision calculated from the 
IQC from low and high levels of the IQC for each 
analyte is given in Table 1. At an A-zone width of 
12% all assays had less than 50 measurements per 














Figure 1. The A-zone. 
The dotted lines around the equal line (hatched line) of dupli-
cate measurements represent the A-zone, the first measure-
ment on the X-axis and the second measurement on the Y-axis. 
The A-zone width can be modified symmetrically around the 
equal line as indicated by the arrows. The triangles represent 
a duplicate measurement within the chosen A-zone whereas 
the square represents a duplicate measurement outside the A-
zone.
Figure 2. Analytical performance of nine assays. The frequency 
(per mille) of observed differences in duplicate measurements, 
which were outside a given width of the zone of acceptance 
(A-zone). AZ95, (the width of the A-zone comprising 95% of the 
observations) for each assay is given on the X-axis where the 
horizontal red line crosses the curves of the assays. The OPM 
(the relative number of observations in 1000 observations out-
side the A-zone) at an A-zone width of 5% can be read from the 
red vertical line. Horizontal lines crossing assay lines are in the 
following order: calcium, TSH, cholesterol, ALT, triglycerides, 
AST, lactate, creatinine and CRP. Assays that cross the shaded 
area in the left-hand corner comprise 95% of the observations 
with an A-zone width lower than 5% and have fewer than 50 per 
mille outliers at an A-zone of 5%.
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Measurand
(Measuring interval according to the 
manufacturer´s instructions)
RiliBÄK





(target value IQC 
low level)
CV (%),
(target value IQC 
high level)
ALT* (6 - 1002 U/L) 30–300 5620 3.1–5.0(42 U/L)
2.8–3.6
(105 U/L)
AST* (3 – 1002 U/L) 19.8–400.2 11,797 2.1–5.7(36 U/L)
0.8–1.5
(194 U/L)
Calcium* (1.25 - 3.75 mmol/L) 1.00–6.00 65,077 1.1–2.4(2.41 mmol/L)
1.0–2.2
(2.85 mmol/L)
Cholesterol* (1.29 - 15.54 mmol/L) 1.3–9.1 12,092 1.7–5.2(5.1 mmol/L)
1.8–5.4
(2.74 mmol/L)
Creatinine* (9 – 1768 µmol/L) 44–884 73,242 2.2–7.5(118 µmol/L)
0.9–3.8
(629 µmol/L)
CRP† (3.1 – 190 mg/L) 1–120 27,836 2.4–6.1(52 mg/L)
2.3–7.0
(12.1 mg/L)
Lactate* (0.1 – 15 mmol/L) 1–10 1596 1.2–4.4(2.42 mmol/L)
1.2–8.3
(5.71 mmol/L)
Triglycerides* (0.02 - 11.3 mmol/L) 0.68–4.6 17,094 1.3–3.8(2.35 mmol/L)
1.6–4.5
(1.35 mmol/L)
TSH# (0.005 – 100 mU/L) 0.1–40 23,321 2.0–4.3(0.27 mU/L)
1.8–3.6
(16.4 mU/L)
*IQC were performed using 1AQ104 TRU-Liquid Monitrol (Thermo Fisher Scientific, Schwerte, Germany).
#IQC Was performed using 9LQ105 Liquimmune (Thermo Fisher Scientific, Schwerte, Germany). 
†IQC Was performed using 1LQH01 Protein2 (Siemens Healthcare Diagnostics, Eschborn Germany).
CV – coefficient of variation. Conversion factor from SI Unit to Conventional Unit for enzymes is 60. AST - aspartate 
aminotransferase; ALT - alanine aminotransferase; CRP – C – reactive protein; TSH - thyroid-stimulating hormone.
Table 1. Basic data on studied assays and imprecision calculated from IQC. 
ymptotical decrease. In consideration of the as-
ymptotical curve at widen A-zone width we limit-
ed the width of the A-zone to 14%.
The number of outliers relative to the A-zone 
width is shown in Figure 2:
1. AZ95 is read on the X-axis in figure 2 where the 
horizontal red line crosses the curves of the as-
says. The AZ95 ranges from 3.2% for calcium 
to 11.3% for CRP. Triglycerides and ALT have an 
AZ95 of 5.5%, which is below the values found 
for lactate, AST, creatinine and CRP, but above 
those found for calcium, TSH and cholesterol. 
2. OPM can be read from the vertical red line in 
Figure 2. An OPM of 5 per mille can be found for 
calcium and up to 250 per mille for CRP and cre-
atinine. Values found for AST, lactate, creatinine 
and CRP indicate a poorer performance, i.e. a 
higher relative number of outliers than triglyc-
erides, ALT, cholesterol, TSH and calcium. 
Only three out of the investigated nine assays (cal-
cium, TSH, and cholesterol) have
•	 an A-zone width equal to or lower than 5% and 
including 95% of the observations and
•	 equal to or fewer than 50 per mille outliers at an 
A-zone of 5%.
The curves of these assays cross the shaded area in 
the lower left corner in Figure 2. 
Discussion
We used a large number of duplicate measure-
ments to describe the performance and analytical 
robustness of assays.
We introduce two new quality markers for describ-
ing analytical quality (AZ95 and OPM): The AZ95 
(width of the A-zone covering 95% of the observa-
tions for an assay) was chosen in analogy to the 
95% confidence interval and represents the first of 
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the two suggested quality markers (horizontal red 
line, Figure 2). It ranges from about 3.2% for calci-
um to 11.3% for CRP. 
In a clinical setting, relative terms may be difficult 
to handle. Therefore, we translate our findings into 
absolute terms. When assuming that the first 
measured value represents a measurement on the 
equal line, the AZ95 for calcium was found to be 
3.2%. Therefore, at a calcium concentration of 2.0 
mmol/L, 95% of all duplicate measurements could 
be expected between 1.94 and 2.06 mmol/L, 
whereas for a creatinine concentration of 100 
µmol/L it would be between 90 and 110 µmol/L 
since its AZ95 was determined at 10.3%. Still, 5% of 
all measurements will deviate more. For glucose 
the A-zone width which comprises 95% of all ob-
servations was reported in the previous study, 
which used the same instrument, to be approxi-
mately 4% (27). This previously reported perfor-
mance for glucose is comparable to our findings 
for calcium.
The second suggested quality marker OPM is the 
relative number of observations outside the A-
zone in per mille at an A-zone width of 5% (vertical 
line, Figure 2). Calcium shows the best perfor-
mance with an OPM of 5 in 1000 measurements. 
Translated into clinical terms: at calcium concen-
tration of 2.0 mmol/L ± 0.1 mmol/L the clinician 
would have to accept an outlier frequency of 5 per 
mille, i.e. in only 5 cases out of 1000 measure-
ments. For CRP (e.g. at 5.0 mg/L ± 0.25 mg/L) and 
creatinine (e.g. at 100 µmol/L ± 5.0 µmol/L) the 
OPM is 210 and 250 in 1000 measurements, re-
spectively (extrapolated from Figure 2). The initial 
study reported less than 10 per mille outside an A-
zone width of 5% for glucose based on 21,000 du-
plicate measurements and therefore its perfor-
mance is comparable to calcium in this study (27).
According to the quality markers, AZ95 and OPM 
used in the present study three assays (calcium, 
TSH and cholesterol) show the best analytical ro-
bustness and performance of all investigated as-
says with an A-zone width that comprises 95% of 
the observations that is lower than 5% and fewer 
than 50 per mille outliers at an A-zone of 5%. Both 
criteria have been reported to be fulfilled also for 
glucose (27). Deetz et al. investigated duplicate 
measurements applying College of American Pa-
thologists (CAP)/Clinical Laboratory Improvement 
Amendments (CLIA) error limits to identify outliers 
and report 0.2% outliers out of 3000 observations 
for calcium which corresponds to an AZ95 of 
about 2.5% (22). This study is in line with our find-
ings for calcium, which showed a very low fre-
quency of extreme differences compared to other 
assays. Whereas Deetz et al. investigated about 
3000 observations for calcium, other assays had 
100 observations or less (22,29). Onyenekwu et al. 
found 4.9% outliers out of 91 repeats for calcium 
at critical concentrations also using CAP/CLIA er-
rors limits (21). Witte et al. aimed to identify outli-
ers in the sense of “errors” defined by a multiple 
SD e.g. 6 or 7 SD and therefore report a compara-
tively low frequency of 41 in one million results 
(0.041 per mille) (29).
Due to the heterogeneous approaches, results of 
different studies cannot be easily compared. In 
contrast to previous studies, our model represents 
a flexible approach to search for differences or 
outliers of various definitions by widening or re-
ducing the A-zone accordingly. Rather than a fixed 
or statistically based definition of outliers, we eval-
uated the frequency of extreme differences of di-
verse magnitudes in relation to a distribution of 
observed duplicates around an equal line assum-
ing identity of duplicates. In addition to precision 
and trueness, the frequency of outliers should be 
considered to describe the analytical quality of an 
assay (30). 
Our findings describe what is presently accepted 
in clinical practice, i.e. the “state of the art”. To fa-
cilitate comparability between laboratories and 
assays we suggest the fixed quality markers AZ95 
and OPM in analogy to the 95% confidence inter-
val, but our model also allows for individual ad-
justments. The results of our study complement 
performance criteria of assays and may be used for 
discussing potentials and limitation of assays be-
tween clinicians and laboratorians. Furthermore, 
this approach can aid the selection process of 
measurement procedures in view of clinical needs. 
Due to limited resources, we focused on nine com-
monly used assays. The number of duplicates was 
below 10,000 for three assays, which limits the de-
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tection of very low frequencies of extreme differ-
ences and outliers. These assays showed OPMs of 
approximately 55 (ALT) and 90 (lactate) which can 
be sufficiently identified by 5600 and 1500 dupli-
cates, respectively. 
In conclusion, duplicate measurements of large 
numbers of patient samples identify even low fre-
quencies of extreme differences. We suggest two 
additional quality markers to describe perfor-
mance and robustness of assays and report what 
is currently accepted in clinical practice: 1. AZ95: 
width of an A-zone containing 95% of all duplicate 
measurements, and 2. OPM: the relative number 
(in per mille) of outliers if an A-zone width of 5% is 
used to identify outliers. Out of the investigated 
nine common assays calcium, TSH, and cholesterol 
have an A-zone width comprising 95% of the ob-
servations that is lower than 5% and have fewer 
than 50 per mille outliers at an A-zone of 5. Our 
findings complement performance criteria of as-
says and can aid the selection process of measure-
ment procedures in view of clinical needs.  
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